- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
PD-1/PD-L1 binding studies using microscale thermophoresis ; volume:7 ; number:1 ; day:15 ; month:12 ; year:2017 ; pages:1-8 ; date:12.2017
Scientific reports ; 7, Heft 1 (15.12.2017), 1-8, 12.2017
- Klassifikation
-
Biowissenschaften, Biologie
- Urheber
-
Magnez, Romain
Thiroux, Bryan
Taront, Solenne
Segaoula, Zacharie
Quesnel, Bruno
Thuru, Xavier
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-17963-1
- URN
-
urn:nbn:de:101:1-2019102021485760158865
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:26 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Magnez, Romain
- Thiroux, Bryan
- Taront, Solenne
- Segaoula, Zacharie
- Quesnel, Bruno
- Thuru, Xavier
- SpringerLink (Online service)
Ähnliche Objekte (12)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
PD-L1 Expression als Prognosemarker beim Endometriumkarzinom
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Regulatory mechanisms of PD-1/PD-L1 in cancers
The PD-1:PD-L1 axis in Inflammatory Arthritis
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Expression von PD-L1 und PD-1 im kleinzelligen Lungenkarzinom
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors